- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Commercial Insurers Also Drag Feet on Covering Generics
Trade group had previously documented even slower coverage by Part D plans.
Commercial insurers, not just Medicare D plans, are slow in covering new generics, according to a white paper released today by the Association for Accessible Medicines, the trade association for the generics and biosimilars industry.
Still, by the association’s reckoning, commercial insurers are doing better job of covering generics than Part D plans.
Today’s white paper is a follow-up to a
white paperthe association put out in September that showed that it takes nearly three years before first generics are covered on a little more than 50% of Medicare Part D formularies. The association says rebates and the mandatory discounts on branded drugs in Part D wind up disadvantaging generics, and it has called for rules that would ensure the Part D plans cover generics when they launch and that generics would be listed on generic tier.
Related: Generics of Older Drugs Could Have Saved Medicare Billions, Study Says
Today’s white paper says commercial health plans also drag their feet in covering generics, although not as much as Part D plans do. When the association’s researchers analyzed 600 commercial formularies, they found that about 75% of them were covering new generics three years after they were launched-but, they noted, that coverage plateaus after two years. "Policymakers should examine whether this data signals a worsening coverage trend," says the white paper.
The association research found that 90% of the time commercial insurer put generics on lower-cost generic tiers in their formularies-the placement that the association wants-and that placement on that tier inches up over the next several years.
In contrast-the according to the association’s research-Part D plans put first generics on the generic tier about 50% of the time and then tend to move first generics to higher tiers in subsequent years.
A Conversation With Greg Baker, RPh, CEO of AffirmedRx
March 31st 2024Greg Baker, CEO of AffirmedRx, describes his early career, shares some of his critical opinions about the pharmacy benefit management (PBM) industry and how, in his view, his company is offering a better alternative.
Read More
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Florida Gets the OK. But Will Drug Importation from Canada Actually Happen?
March 5th 2024Canadian health officials warn that maintaining a drug supply for Canadians is their priority. The staunch opposition of the U.S. pharmaceutical industry may also be an obstacle to imports from north of the border.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
What Payers Need to Know As Retail Pharmacies Move Into Primary Care
September 6th 2023Healthcare beyond the doors of the doctor’s office has the potential to offer more care to more people. But payers need to think about how to ensure that care is consistent. Regardless of the setting, care decisions must be based on evidence-based content and supported with strong patient education.
Read More
